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New variant and expression studies 
provide further insight into the 
genotype-phenotype correlation in 
YAP1-related developmental eye 
disorders
R. Holt1, F. Ceroni1, D. A. Bax1, S. Broadgate1,2, D. Gold Diaz3, C. Santos3, D. Gerrelli3 &  
N. K. Ragge1,4
YAP1, which encodes the Yes-associated protein 1, is part of the Hippo pathway involved in 
development, growth, repair and homeostasis. Nonsense YAP1 mutations have been shown to co-
segregate with autosomal dominantly inherited coloboma. Therefore, we screened YAP1 for variants in 
a cohort of 258 undiagnosed UK patients with developmental eye disorders, including anophthalmia, 
microphthalmia and coloboma. We identified a novel 1 bp deletion in YAP1 in a boy with bilateral 
microphthalmia and bilateral chorioretinal coloboma. This variant is located in the coding region of 
all nine YAP1 spliceforms, and results in a frameshift and subsequent premature termination codon 
in each. The variant is predicted to result in the loss of part of the transactivation domain of YAP1, 
and sequencing of cDNA from the patient shows it does not result in nonsense mediated decay. To 
investigate the role of YAP1 in human eye development, we performed in situ hybridisation utilising 
human embryonic tissue, and observed expression in the developing eye, neural tube, brain and 
kidney. These findings help confirm the role of YAP1 and the Hippo developmental pathway in human 
eye development and its associated anomalies and demonstrate its expression during development in 
affected organ systems.
Developmental eye anomalies, including anophthalmia (absent eye), microphthalmia (small eye) and coloboma 
(gap in the eye structure) (AMC) are a genetically heterogeneous group of disorders affecting 11.9 per 100,000 
live births1. Increasing numbers of causative genes have been identified for these anomalies, including SOX22, 
OTX23, BMP44, BMP75 and STRA66. Recently, Williamson et al. reported two large pedigrees each containing 
multiple individuals with developmental eye anomalies which were inherited in an autosomal dominant fashion. 
In both families they identified co-segregating heterozygous nonsense mutations in YAP17. In addition to the eye 
anomalies, affected members of one family also exhibited variable extraocular features including hearing loss, 
intellectual disability, haematuria and orofacial clefting7, 8. Further screening of YAP1 in a large cohort of individ-
uals with eye anomalies identified an additional four variants classified as of unknown pathogenicity for various 
reasons: being inherited from an unaffected parent (1 case), parental DNA being unavailable (2 cases), or as the 
mutation was a copy number variant affecting multiple genes, including YAP1 (1 case)7. Similarly, Oatts et al. 
identified a novel heterozygous mutation in a family with coloboma and microphthalmia with evidence of incom-
plete penetrance9. Finally, Fossdal et al. identified a mutation of TEAD1, a cofactor of YAP1, as a cause of helicoid 
peripapillary chorioretinal degeneration. The mutation occurs in a potential binding site for YAP1, leading them 
to postulate that the change alters the ability of YAP1 to bind TEAD1, affecting the expression of other genes10.
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YAP1 is a transcriptional co-activator, and in combination with TAZ (encoded by WWTR1), is a major 
effector of the Hippo pathway to regulate organ size, binding TEAD1-4 to promote transcription11, 12 (Fig. 1). 
Activation of the Hippo pathway results in phosphorylation of YAP1 and TAZ, causing their migration from the 
nucleus to the cytoplasm, thus inhibiting their effect on transcription11. YAP1 expression is positively correlated 
with that of SOX211, 13. Furthermore, reduction in SOX2 expression also correlates with decreased expression of 
multiple targets of YAP/TEAD11. YAP1 is directly regulated by SOX2, which is able to bind a CpG island 5′ of 
exon 1, as well as to exon 211, 13. YAP1 also binds β-catenin and therefore may affect β-catenin-dependent Wnt 
signalling13. Zebrafish Yap1 mutants (yapnl13/nl13 and c.158_161del mutant lines, respectively) exhibit colobomas 
and loss of retinal pigment epithelium (RPE) in a fully penetrant fashion, but with varying extent and localisation, 
including asymmetric eye involvement in a single fish14. Typically, deficiency in RPE mainly occurs in the pos-
terior part of the eye, but also affects the lateral and ventral surfaces14. Interestingly, medaka (Japanese rice fish) 
Yap hir mutants have a flattened body shape and mislocalisation of the lens to outside of the eye, due to loss of 
the filopodia normally tethering them to the retina. Therefore, Yap is essential for tissue tension and body shape 
in medaka15. YAP1 and TAZ have also been shown to be expressed in the human adult cornea16. Furthermore, a 
large number of genes and proteins in the pathways with which YAP1 interacts have been implicated in AMC or 
eye function (Fig. 1).
Therefore, we screened YAP1 in our UK cohort of patients with developmental eye anomalies to determine 
whether any potentially pathogenic variants were present.
Results
Patient screening. A UK cohort with ocular anomalies, principally anophthalmia, microphthalmia, and 
coloboma (AMC), was recruited as part of a national ‘Genetics of Eye and Brain anomalies’ study (REC study 
number 04/Q0104/129). In total, 258 UK patients were screened for variations in the coding region and flanking 
sequences of YAP1 using LightScanner high resolution analysis17 with subsequent validation by Sanger sequenc-
ing. A novel heterozygous single base pair deletion variant was identified in exon 7 of case 1 (NM_001130145; 
exon7; c.1160delA; NP_001123617; p.Asn387Thrfs*16), observed by sequencing in both orientations. This var-
iant was not present in the databases dbSNP147, ExAC18 or gnomAD18. Parental DNA samples were sequenced 
for both strands of exon 7, and the variant was identified in the heterozygous state in the asymptomatic father 
(Fig. 2). This variant occurs at chr11:102,223,749 (GRCh38/hg38) within the coding region of YAP1. There are 
nine known splice variants of YAP1 encoding proteins of between 326 and 508 amino acids. All contain exon 7 
and are predicted to have a frameshift in the presence of the variant, resulting in a premature termination codon, 
16 codons after that in which the deletion occurs, leading to the loss of 118 amino acids that form part of the 
transactivation domain of the protein, the region required for the binding of other proteins. However, the pre-
mature termination codon is located 69 nucleotides upstream from the final exon-exon junction and therefore it 
could cause the nonsense mediated decay of all transcripts of YAP1 containing it19. In addition, the c.1160delA 
Figure 1. Cartoon illustrating the pathways with which YAP1 interacts. Known anophthalmia, microphthalmia 
and coloboma genes are coloured red. Genes implicated in eye function are coloured yellow. Genes not yet 
implicated in eye development or function are coloured blue.
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occurs four nucleotides from the 3′ end of exon 7 and therefore could potentially affect splicing of the mRNA. 
Analysis of the mutation using the online tool Human Splicing Finder (http://www.umd.be/HSF3/index.html)20 
indicated that the variant might alter YAP1 splicing by alteration of an exonic splicing enhancer or suppressor site, 
or by activation of a cryptic donor site.
Figure 2. Identification of a novel YAP1 frameshift mutation in a patient with developmental eye disorders. 
(a) The mutation is heterozygous in the patient and inherited from his asymptomatic father. (b) Schematic 
of the genomic structure of YAP1. Exons are indicated by boxes and are drawn to scale with the exception of 
the untranslated regions (shown as solid black boxes). Exon and intron sizes are shown beneath. Initiation 
and termination codons are indicated, with the alternate initiation codon of the NM_001195045.1 transcript 
indicated in red. The positions of the c.1160delA (p.Asn387Thrfs*16) reported here and the co-segregating 
nonsense mutations identified by Williamson et al.7 and the missense mutation identified by Oatts et al.9 are 
indicated. Alt. 1 = alternative exon 1 (NM_001195045.1 transcript). (c) The p.Asn387Thrfs*16 variant is located 
within the transactivation domain of YAP1 (NP_001123617). The locations of the co-segregating nonsense 
mutations identified by Williamson et al.7 and the missense mutation identified by Oatts et al.9 are also shown.
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YAP1 expression in Case 1. To determine whether the c.1160delA variant does alter splicing or cause 
nonsense mediated decay, RNA was obtained from a Case 1 saliva sample using Oragene RNA kits and cDNA 
generated by reverse transcription. PCR of the cDNA for 45 cycles using forward and reverse primers in YAP1 
exons 7 and 9, respectively, resulted in a strong primary band of the expected size of 549 bp and a weak secondary 
band of approximately 350 bp. No bands were present in control PCRs using the products of reverse transcription 
reactions lacking reverse transcriptase, indicating the results were not due to genomic DNA contamination. Gel 
purification and sequencing of the stronger band revealed the presence of transcripts both with and without the 
c.1160delA variant, whereas sequencing for the secondary band failed. RNA was unavailable for either of Case 1’s 
parents. Thus, the mutation does not lead to either alternate splicing or nonsense mediated decay.
Case description. The case presented is a 9 year old boy born via a normal delivery at 42 weeks’ gestation 
with a birth weight of 8 lb 6 oz. He has bilateral microphthalmia with a corneal diameter of 8mm on the right and 
4mm on the left. This was associated with bilateral chorioretinal coloboma more marked on the left, bilateral pos-
terior embryotoxon, nystagmus and a small left convergent squint. His developmental milestones were normal, 
but he was diagnosed with Asperger’s syndrome at age 5 years. His growth parameters are within normal range, 
although tracking along the lower centiles, with his height between the 2nd and 9th centile, his weight on the 25th 
centile and his head circumference between the 2nd and 9th centile at 9 years of age. Urine analysis was normal. 
Karyotyping and array CGH results were normal. No other systemic abnormalities were observed. Both parents 
had a normal eye examination.
YAP1 expression during human development. As microphthalmia and coloboma are due to aberra-
tions during eye development, we examined YAP1 expression in human embryonic brain and eye. Furthermore, 
as haematuria has been reported in some patients with YAP1 mutations7, 8, 21, we also examined expression in 
the human embryonic kidney. Nonradioactive RNA in situ hybridisation was performed on human embryo sec-
tions at Carnegie Stages (CS) 15, 17, 21 and 224. Human embryos were obtained from the MRC/Wellcome Trust 
Human Developmental Biology Resource, UCL, with full ethical approval. YAP1 expression was observed in 
multiple structures at CS15 (Fig. 3a,b,e–h). Of immediate relevance to the phenotype of Case 1 was expression in 
the developing eye, including the retina. Further expression was found in the ectoderm forming Rathke’s pouch, 
which advances during development to form the adenohypophysis (anterior pituitary). YAP1 was also expressed 
in the otic vesicle (primitive ear), the region surrounding the ventricle of the diencephalon, which forms part of 
the forebrain, the tissue of the rhombencephalon (hindbrain), as well as the trigeminal ganglion. In contrast, by 
CS17 the most prominent expression was observed in the retina, diencephalic superventricle, neural tube, and 
the primordium of the lateral palatine process (Fig. 3c,d,i–l). Expression in the retina continued to be observed at 
CS21 (Fig. 3m,n), and was also observed in the renal tubules of the developing kidney at CS22 (Fig. 3o,p).
Discussion
In this study we identify a novel frameshift mutation in a boy with bilateral microphthalmia and bilateral chori-
oretinal coloboma, inherited from his unaffected father. We show that this mutation does not affect splicing and 
does not lead to nonsense mediated decay of the mRNA. We demonstrate that YAP1 is expressed in multiple 
structures in the developing human embryo, including the retina, brain and kidney.
Mutations in YAP1 have been associated with both syndromic and non-syndromic forms of developmen-
tal eye disorders7. It has been suggested that this is related to whether the variant affects a single or multiple 
transcripts of the gene, with the former being related to the nonsyndromic form, and the latter to a syndromic 
phenotype7, 9. However, the p.Asn387Thrfs*16 frameshift reported here is located within exon 7 of YAP1 and 
is predicted to affect all known splice forms, yet with the exception of Asperger’s syndrome the patient has no 
extraocular phenotype. This novel frameshift mutation was inherited from an asymptomatic parent. However, 
variable expressivity in relation to YAP1 mutations has been previously reported in humans7, as well as in 
zebrafish models14. In addition, it is possible that the case contains a modifying mutation within a second gene 
which would account for the difference in phenotypes between father and child. Alternatively, it is possible that 
the mutation arose de novo in the father as a mosaic alteration, accounting for his lack of an AMC phenotype. 
Unfortunately, DNA was unavailable from the paternal grandparents to test this hypothesis. Our in situ data iden-
tified sequential expression of YAP1 in relevant structures of the developing human eye, to our knowledge the first 
time this has been shown. Expression within the developing retina is consistent with the chorioretinal colobomas 
reported in Case 1, as well as those in previously described families7, 9. This is further supported by data showing 
that optic vesicle progenitor cells in zebrafish Yap1 mutants lose their ability to form RPE14. Interestingly, given 
the presence of haematuria and deafness in one previously reported family with a YAP1 nonsense mutation7, 8, 21, 
we also identified expression within the developing kidney and otic vesicle, consistent with its relevance to these 
additional phenotypes. The presence of Asperger’s syndrome in Case 1 is intriguing, given reports of intellectual 
disability in other families with YAP1 alterations7 and our demonstration of YAP1 expression in multiple regions 
of the developing human brain. However, due to the genetic complexity of autism spectrum disorders22, such 
correlations must still be approached with caution. Finally, the YAP1 phenotypes observed in Case 1 and those 
previously reported are less severe than for mutations in SOX22, 3, 7, 9, 23. SOX2 is able to directly regulate YAP113, 
indicating that as a downstream gene the range of its effects is less, consistent with more moderate phenotypes. 
Therefore, this study contributes to the evidence for the role of YAP1 mutations as a rare cause of developmental 
eye disorders and demonstrates its expression in multiple tissues during human development, highlighting the 
importance of screening this gene in patients with other phenotypes, including deafness and haematuria.
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Figure 3. YAP1 in situ hybridisation studies in the developing human. (a,b) In situ hybridisations of coronal 
sections of a CS15 human fetus using YAP1 antisense (a) and sense (negative control) (b) probes reveal 
expression in structures including the diencephalic superventricle (future third ventricle), retinal ganglion cell 
layer, Rathke’s pouch (future pituitary), trigeminal ganglion, otic vesicle, and rhombencephalon (future fourth 
ventricle). (c,d) In situ hybridisations of coronal sagittal sections of a CS17 human fetus using YAP1 antisense 
(c) and sense (negative control) (d) show expression of YAP1 in diencephalic superventricle, retina, primordium 
of the lateral palatine process, and neural tube. (e–h) High magnification images of YAP1 expression in the 
CS15 human fetus in multiple structures: (e) retinal ganglion cell layer, (f) diencephalic superventricle and 
Rathke’s pouch, (g) otic vesicle, and (h) rhombencephalon. (i–l) High magnification images of YAP1 expression 
in the CS17 human fetus in multiple structures: (i) retina, (j) primordium of the lateral palatine process, (k) 
diencephalic superventricle, and (l) the neural tube. (m,n) High magnification images of YAP1 expression 
in the retina of CS21 human fetus: (m) antisense, and (n) sense. (o,p) High magnification images of YAP1 
expression in the kidney of CS22 human fetus: (o) antisense, and (p) sense. Abbreviations: DS = diencephalic 
superventricle; L = lens; NT = neural tube; OV = otic vesicle; PP = primordium of the lateral palatine process; 
R = retina; RG = retinal ganglion cell layer; Rh = rhombencephalon; RP = Rathke’s pouch; RT = renal tubules; 
TG = trigeminal ganglion.
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Methods
Cohort Description. A UK cohort with ocular anomalies, principally AMC, was recruited as part of a 
national ‘Genetics of Eye and Brain anomalies’ study with ethical approval from the Regional Ethics Committee 
Cambridge East (REC study number 04/Q0104/129). Participant informed consent was obtained according to 
the tenets of the Declaration of Helsinki. Patients were screened by indication in known AMC genes. From this 
cohort 258 individuals without a genetic diagnosis were screened for variants in YAP1. Of these, 32 individu-
als had bilateral anophthalmia or unilateral anophthalmia with contralateral microphthalmia, 43 had bilateral 
microphthalmia (+/−coloboma), 146 had unilateral anophthalmia/microphthalmia (+/−contralateral defects), 
and 37 had other phenotypes, including anterior segment dysgenesis. All subsequent experiments utilising the 
patient samples were performed in accordance with the relevant guidelines and regulations.
Mutation Analysis. All nine coding exons of YAP1 (NM_001282101.1), the alternate second exon of 
NM_001195045.1, and flanking sequences were screened for mutations by high resolution melting curve analysis 
on a LightScanner® (Idaho Technology Inc). PCRs for LightScanner melt curve analysis consisted of 10ng of 
template DNA, and final concentrations of 0.25 µM of each primer, 1x HotShot Diamond Master Mix (ClentLife) 
and 1x LCGreen Plus Dye (BioFire Diagnostics Inc) in a total volume of 10 µl. PCRs were typically one cycle of 
5 minutes 95 °C, 45 cycles of 95 °C 30 s, annealing temperature 30 s and 72 °C 45 s, followed by a final denaturation 
step of 95 °C for 30 s. PCRs were performed in Framestar® 96 (4titude) 96-well plates with a 20 µl mineral oil 
overlay. Melt curves were generated on a LightScanner® (Idaho Technology Inc) using autoexposure, a starting 
temperature of 75 °C and a stop temperature of 98 °C. Data was analysed using the LightScanner® Instrument & 
Analysis Software (Idaho Technology Inc). Melt curves were normalised prior and post the major melt transi-
tion and aberrant curves detected using the autogroup function and manual inspection. Samples with an initial 
fluorescence of less than 600 were excluded from analysis, while those with a starting fluorescence less than 
800 were not included during normalisation. Samples with aberrant melt curves were analysed using Sanger 
sequencing (primers available upon request) and sequence data analysed using CodonCode Aligner (CodonCode 
Corporation, Dedham, MA) or Chromas (Technelysium).
RNA extraction and reverse transcription. RNA was extracted from saliva samples using Oragene® 
RNA kits (DNA Genotek) following the manufacturer’s instructions. Reverse transcription was performed using 
a QuantiTect Reverse Transcription kit (Qiagen) following the manufacturer’s instructions. Resulting RNA con-
centrations were determined using a NanoDropTM One (Nanodrop).
cDNA PCR. PCRs consisted of 5 µl of template cDNA, and final concentrations of 0.25 µM of each primer, 
1x HotShot Diamond Master Mix (ClentLife) in a total volume of 10 µl. PCRs were one cycle of 5 minutes 95 °C, 
45 cycles of 95 °C for 30 s, 60 °C for 30 s and 72 °C for 45 s. The forward (AGTTACCAACACTGGAGCAG) and 
reverse (AAACTGCAACTGGCTTATGGA) primers were designed to anneal to exon 7 and the 3′ UTR of YAP1, 
respectively.
PCR gel purification. PCR products were purified from agarose gels by band excision using a QIAquick Gel 
Extraction kit (Qiagen), following the manufacturer’s protocol.
In Situ Hybridisation. Nonradioactive RNA in situ hybridisation was performed on human embryo 
sections at Carnegie Stages (CS) 15, 17, 21 and 22 as described elsewhere4. Probes were designed within the 
3′ UTR of YAP1 to bind all known splice variants and generated using primers GCTCGGCGGCCGCACTT 
GCTCCTACTTCTATGCTGA and GCTCGGTCGACGGCACTCCTTCCAAGTAGCT. Human embryos 
were obtained from the MRC/Wellcome Trust Human Developmental Biology Resource, UCL, with full ethical 
approval.
Data Availability. No datasets were generated or analysed during the current study.
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